New stock news | Rongtai Pharmaceutical's Hong Kong IPO prospectus invalid

Guangdong Rongtai Pharmaceutical Co., Ltd. (referred to as Rongtai Pharmaceutical) submitted its Hong Kong IPO prospectus on September 26, 2025, which expired after 6 months on March 26, 2026. CITIC SEC was its exclusive sponsor at the time of submission. According to the previous prospectus, Rongtai Pharmaceutical is a leading extra-hospital pharmaceutical service provider in China, focusing on digital marketing and supply chain solutions. According to Frost & Sullivan data based on 2024 revenue, the company is the fourth largest marketing and supply chain solution provider in the Chinese extra-hospital pharmaceutical market, as well as the largest marketing and supply chain solution provider for individual customers in the Chinese extra-hospital pharmaceutical market. The company has independently developed a digital precision marketing system and integrated digital business and data platforms with intelligent logistics infrastructure to provide pharmaceutical companies with full-process, omni-channel medical sales solutions. The company plays a key role in the e-commerce sales channels of pharmaceutical companies, matching them with the best e-commerce sales resources. After purchasing pharmaceutical products from upstream pharmaceutical companies or their authorized distributors, the company sells the products to individual customers through B2C and O2O e-commerce platforms such as JD HEALTH, ALI HEALTH, Meituan Health, Dingdang, and Quanyuantang. The company also provides pharmaceutical companies with multi-dimensional e-commerce empowerment services, including integrated brand operations, refined data monitoring and management, omni-channel traceability capabilities, and intelligent inventory management solutions. In this model, the company serves as an important bridge between pharmaceutical companies and individual customers.